Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
TEKTURNA |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Direct renin inhibitor. |
| Generic Name |
|
Aliskiren 150mg, 300mg; tabs. |
| Indications |
|
Hypertension. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: initially 150mg once daily, may increase to 300mg once daily if BP not adequately controlled. May be given with other antihypertensives (see literature). |
| Precautions |
|
Moderate to severe renal dysfunction. History of dialysis. Nephrotic syndrome. Renovascular hypertension. Correct salt/volume depletion before starting therapy or start under close supervision. Monitor for hyperkalemia in diabetics. Pregnancy (Cat.C in 1st trimester; Cat.D 2nd and 3rd trimesters); discontinue as soon as pregnancy detected. Nursing mothers: not recommended. |
| Interactions |
|
Decreases furosemide plasma levels; may have diminished effect. Potentiated by atorvastatin, ketoconazole. Antagonized by irbesartan. Caution with max doses of ACE inhibitors. |
| Adverse Reactions |
|
Diarrhea, hypotension, cough, rash, edema, elevated uric acid, gout, renal stones; rare: angioedema. |
| How Supplied |
|
Tabs—30, 90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
